Comments
Pfizer arthritis drug wins approval, to challenge Humira
07.11.2012. | (Reuters) - U.S. regulators on Tuesday approved Pfizer Inc's Xeljanz treatment for rheumatoid arthritis, one of the company's most potentially lucrative experimental drugs, which is now poised to compete with Abbott Laboratories Inc's top-selling Humira....
